Shots:
- Novavax will supply ~60M doses of its COVID-19 vaccine to the UK government for P-III study evaluating the efficacy of NVX-CoV2373 in ~9,000 adults aged 18-85yrs. in the UK. The trial is expected to initiate in Q3’20
- Novavax will expand its collaboration with FUJIFILM Diosynth, which will manufacture the antigen component of NVX-CoV2373 from its Billingham, Stockton-on-Tees site in the UK, in addition to its sites in NC and Texas in the US
- The FUJIFILM Diosynth site in the UK is expected to produce up to 180M doses annually, which boosts the global supply of NVX-CoV2373 for additional markets. NVX‑CoV2373 elicited robust Ab responses superior to seen in human convalescent sera in P-I/II clinical study while P-II study is expected to begin in Aug’2020
Click here to read full press release/ article | Ref: Novavax | Image: Reuters